Citation
Thakkar, Vivek, et al. "The Role of Asymmetric Dimethylarginine Alone and in Combination With N-terminal pro-B-type Natriuretic Peptide as a Screening Biomarker for Systemic Sclerosis-related Pulmonary Arterial Hypertension: a Case Control Study." Clinical and Experimental Rheumatology, vol. 34 Suppl 100, no. 5, 2016, pp. 129-136.
Thakkar V, Stevens W, Prior D, et al. The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study. Clin Exp Rheumatol. 2016;34 Suppl 100(5):129-136.
Thakkar, V., Stevens, W., Prior, D., Rabusa, C., Sahhar, J., Walker, J. G., Roddy, J., Lester, S., Rischmueller, M., Zochling, J., Nash, P., Gabbay, E., Youssef, P., Proudman, S. M., & Nikpour, M. (2016). The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study. Clinical and Experimental Rheumatology, 34 Suppl 100(5), 129-136.
Thakkar V, et al. The Role of Asymmetric Dimethylarginine Alone and in Combination With N-terminal pro-B-type Natriuretic Peptide as a Screening Biomarker for Systemic Sclerosis-related Pulmonary Arterial Hypertension: a Case Control Study. Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):129-136. PubMed PMID: 27214686.
TY - JOUR
T1 - The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study.
AU - Thakkar,Vivek,
AU - Stevens,Wendy,
AU - Prior,David,
AU - Rabusa,Candice,
AU - Sahhar,Joanne,
AU - Walker,Jennifer G,
AU - Roddy,Janet,
AU - Lester,Susan,
AU - Rischmueller,Maureen,
AU - Zochling,Jane,
AU - Nash,Peter,
AU - Gabbay,Eli,
AU - Youssef,Peter,
AU - Proudman,Susanna M,
AU - Nikpour,Mandana,
Y1 - 2016/05/23/
PY - 2015/04/14/received
PY - 2016/01/08/accepted
PY - 2016/10/18/pubmed
PY - 2017/1/18/medline
PY - 2016/5/24/entrez
SP - 129
EP - 136
JF - Clinical and experimental rheumatology
JO - Clin Exp Rheumatol
VL - 34 Suppl 100
IS - 5
N2 - OBJECTIVES: Asymmetric dimethylarginine (ADMA) is a novel biomarker of endothelial cell dysfunction. In this proof of concept study, we sought to evaluate the role of ADMA as a screening biomarker for incident systemic sclerosis-related pulmonary arterial hypertension (SSc-PAH). METHODS: ADMA levels were measured using high performance liquid chromatography in 15 consecutive treatment-naive patients with newly-diagnosed SSc-PAH and compared with 30 SSc-controls without PAH. Logistic regression models were used to evaluate the independent association of ADMA with PAH. The optimal cut-point of ADMA for SSc-PAH screening was determined. NT-proBNP levels were previously measured in the same patients and the optimal cut-point of NT-proBNP of ≥210ng/mL was coupled with the optimal cut-point of ADMA to create a screening model that combined the two biomarkers. RESULTS: The PAH group had significantly higher mean ADMA levels than the control group (0.76±0.14 μM versus 0.59±0.07 μM; p<0.0001). ADMA levels remained significantly associated with PAH after the adjustment for specific disease characteristics, cardiovascular risk factors and other SSc-related vascular complications (all p<0.01). An ADMA level ≥0.7 μM had a sensitivity of 86.7%, specificity of 90.0% and AUC of 0.86 for diagnosing PAH. A screening model that combined an NT-proBNP ≥210ng/mL and/ or ADMA ≥0.7 ng/mL resulted in a sensitivity of 100% and specificity of 90% for the detection of SSc-PAH. CONCLUSIONS: In this small study, use of ADMA in combination with NT-proBNP produced excellent sensitivity and specificity for the non-invasive identification of SSc-PAH. The role of ADMA as a screening biomarker for SSc-PAH merits further evaluation.
SN - 0392-856X
UR - https://www.unboundmedicine.com/medline/citation/27214686/The_role_of_asymmetric_dimethylarginine_alone_and_in_combination_with_N_terminal_pro_B_type_natriuretic_peptide_as_a_screening_biomarker_for_systemic_sclerosis_related_pulmonary_arterial_hypertension:_a_case_control_study_
L2 - http://www.clinexprheumatol.org/pubmed/find-pii.asp?pii=27214686
DB - PRIME
DP - Unbound Medicine
ER -